Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
Gut 2020;0:1–9. doi:10.1136/gutjnl-2020-322248
Seung Won Lee1, Eun Kyo Ha2, Abdullah Özgür Yeniova3, Sung Yong Moon1, So Young Kim4, Hyun Yong Koh5, Jee Myung Yang6, Su Jin Jeong7, Sun Joon Moon8, Joo Young Cho9, In Kyung Yoo9, http://orcid.org/0000-0003-1628-9948Dong Keon Yon7,10
- Magnesium and Vitamin D category listing has
- Overview Magnesium and vitamin D
- Magnesium is vital to Vitamin D in 4 places (maybe 8) – March 2018
- 500 mg of Magnesium for 8 weeks increased Vitamin D about 30 pcnt – RCT July 2020
- Off Topic: Taking a PPI for GERD increases chance of death from heart disease by 2X– Aug 2015
- Drugs that may harm bone (vitamin D needed) -April 2016
- Acid Reflux drugs decrease Vitamin D and Magnesium – Jan 2013
Items in both categories Magnesium and Virus are listed here:
- Magnesium (which increases vitamin D) may fight COVID-19 - Oct 2020
- COVID-19 1.8 X more likely if proton pump inhibitor (which decreases Mg needed for Vitamin D) – Aug 2020
- COVID-19 might be treated with Mg IV and Potassium – July 2020
- COVID-19 prompts awareness of deficiencies of Vitamin D, C and Magnesium - April 6 2020
- Obesity pandemic since 1975 - is it due to Vitamin D, Magnesium, Iodine, adenovirus, or what
- FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) Aug 2017
- Hypomagnesaemia associated with long-term use of PPI - Aug 2014
Objective The adverse effects of proton pump inhibitors (PPIs) have been documented for pneumonia; however, there is no consensus regarding whether the use of PPIs might be harmful regarding the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this regard, we aimed to measure the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing.
Design Data were derived from a Korean nationwide cohort study with propensity score matching. We included 132 316 patients older than 18 years who tested for SARS-CoV-2 between 1 January and 15 May 2020. Endpoints were SARS-CoV-2 positivity (primary) and severe clinical outcomes of COVID-19 (secondary: admission to intensive care unit, administration of invasive ventilation or death).
Results In the entire cohort, there were 111 911 non-users, 14 163 current PPI users and 6242 past PPI users. After propensity score matching, the SARS-CoV-2 test positivity rate was not associated with the current or past use of PPIs. Among patients with confirmed COVID-19, the current use of PPIs conferred a 79% greater risk of severe clinical outcomes of COVID-19, while the relationship with the past use of PPIs remained insignificant. Current PPI use starting within the previous 30 days was associated with a 90% increased risk of severe clinical outcomes of COVID-19.
Conclusion Patients taking PPIs are at increased risk for severe clinical outcomes of COVID-19 but not susceptible to SARS-CoV-2 infection. This suggests that physicians need to assess benefit–risk assessments in the management of acid-related diseases amid the COVID-19 pandemic.COVID-19 1.8 X more likely if proton pump inhibitor (which decreases Mg needed for Vitamin D) – Aug 2020
362 visitors, last modified 07 Aug, 2020,This page is in the following categories (# of items in each category)